Temozolomide-d3(Synonyms: 替莫唑胺 d3)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物,专注于信号通路和疾病研究领域。
Temozolomide-d3 (Synonyms: 替莫唑胺 d3)

Temozolomide-d3 (NSC 362856-d3) 是 Temozolomide 的氘代物。Temozolomide (NSC 362856) 是一种可透过血脑屏障的口服活性的 DNA 烷基化 (DNA alkylating) 剂。Temozolomide 也是一种促自噬 (autophagy) 和促凋亡剂 (apoptosis)。Temozolomide 对以低水平的 O6-烷基鸟嘌呤 DNA 烷基转移酶 (OGAT) 和功能失配修复系统为特征的肿瘤细胞有效。Temozolomide 具有抗肿瘤和抗血管生成作用。

Temozolomide-d3(Synonyms: 替莫唑胺 d3)

Temozolomide-d3 Chemical Structure

CAS No. : 208107-14-6

规格 是否有货
1 mg 询价
5 mg 询价

* Please select Quantity before adding items.

生物活性

Temozolomide-d3 (NSC 362856-d3) is the deuterium labeled Temozolomide. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

197.17

Formula

C6H3D3N6O2

CAS 号

208107-14-6

中文名称

替莫唑胺 d3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4.

    [3]. Mathieu V, et al. Combining Anti-Human VEGF with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008 Dec;10(12):1383-92.

    [4]. Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务